Key Takeaways:
• Game-Changing Efficacy: WINREVAIR™ (sotatercept-csrk) cut clinical worsening risk in PAH by a statistically significant margin in newly diagnosed patients, 72% of whom were on dual background therapy.
• Third Phase 3 Victory: Following STELLAR and ZENITH, the HYPERION study reinforces WINREVAIR’s consistent efficacy across PAH progression stages.
• Accelerated Impact: Merck ended the trial early due to compelling interim results, signaling urgent advancement to real-world clinical application.
WINREVAIR’s Third Phase 3 Win Raises the Bar in Pulmonary Arterial Hypertension (PAH)
Merck’s WINREVAIR continues to build a solid case for early intervention in PAH management. The HYPERION study—its third successful Phase 3 trial—met its primary endpoint by demonstrating a meaningful reduction in time to clinical worsening (TTCW). In a trial of 320 recently diagnosed patients with WHO Group 1 PAH functional class II or III, WINREVAIR, in combination with standard background therapy, significantly lowered risk across critical outcomes including death, hospitalization, or lung transplant. Notably, the majority (72.2%) of patients were only on dual therapy, suggesting WINREVAIR’s potent impact in less intensively treated populations.
Early Trial Termination Underscores Confidence in Clinical Data
HYPERION was stopped early after a positive interim analysis from the ZENITH trial and an encouraging cumulative review across the WINREVAIR clinical program. Merck’s rapid shift to final analysis and transition of all participants to the SOTERIA open-label extension reflects strong internal conviction. The move reinforces the drug’s safety and efficacy profile, and its potential to alter the standard of care. This marks a notable regulatory and strategic milestone for Merck, emphasizing its leadership in pulmonary vascular disease innovation.
Expanding Indications for a First-in-Class Activin Signaling Inhibitor
WINREVAIR is already approved in over 45 countries and stands as the first activin signaling inhibitor to gain FDA approval for PAH. With preclinical data supporting vascular remodeling reversal and improved cardiac function, the drug introduces a novel biological mechanism targeting disease progression. The HYPERION results add to a growing clinical dossier, showing benefit not only in patients long into their PAH journey—as with STELLAR and ZENITH—but now also in those within just 12 months of diagnosis. This expansion of scope enhances WINREVAIR’s positioning as a platform therapeutic across disease stages.
Broader Industry Implications and a Look Ahead
WINREVAIR’s success could reshape treatment guidelines for PAH, encouraging earlier, more aggressive intervention with advanced biologics. With approximately 40,000 PAH patients in the U.S. alone and a five-year mortality rate of ~43%, the promise of improved outcomes in the earliest treatment phases carries significant implications for payers, providers, and patients alike. As Merck prepares to present the full HYPERION results at a major scientific meeting later this year and submit to regulatory agencies, the industry will watch closely for further data validating WINREVAIR’s breakthrough status.
About Merck & Co., Inc
Merck & Co., Inc., known as MSD outside the United States and Canada, is a global biopharmaceutical leader dedicated to improving health and saving lives through innovative medicines, vaccines, and therapies. With over 130 years of scientific excellence, Merck focuses on breakthrough research in areas including oncology, infectious diseases, and cardiovascular health. The company is committed to advancing cutting-edge treatments, fostering global health equity, and operating responsibly to create a sustainable future. For more, visit merck.com.
About sotatercept-csrk (WINREVAIR™)
Sotatercept-csrk (brand name WINREVAIR™) is a first-in-class activin signaling inhibitor approved for the treatment of pulmonary arterial hypertension (PAH) in adults. By modulating the balance between pro-proliferative and anti-proliferative signaling pathways, sotatercept-csrk helps reduce vascular remodeling and improve heart function, leading to increased exercise capacity and reduced risk of clinical worsening events. It is used alongside standard background therapies to provide a novel mechanism of action addressing the progressive nature of PAH.
By
